VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial
Biopharma & Life Sciences

Olema Pharmaceuticals Executive Compensation (FY25)

OLMA · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Sean Bohen
Latest say-on-pay support
=
June 17, 2026
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on Olema Pharmaceuticals

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
Data as of November 4, 2026Latest filing (8-K): June 23, 2026
9 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Olema Pharmaceuticals brief$500Get the executive brief
Velarion Intel, one year, every company
163 figures on this page: 158 cited to the filing that reported them, 5 calculated from figures it prints. See the citations
This company is not required to report a chief executive pay ratio.

More on Olema Pharmaceuticals

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Sean Bohen: $8,130,556 → $3,178,990 (60.9% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Olema Pharmaceuticals' chief executive and what were they paid?
Total compensation for Sean Bohen, President and Chief Executive Officer, came to $3,178,990 in fiscal 2025. Compared with the $8,130,556 reported for fiscal 2024, Bohen's total was 60.9% lower.
What was Olema Pharmaceuticals' say-on-pay result?
The say-on-pay proposal drew 99.0% support at the meeting held June 17, 2026 for fiscal 2025.
Which companies are in Olema Pharmaceuticals' peer group?
The disclosed peer group names Alector, Alumis, Amylyx Pharmaceuticals (amlx), AnaptysBio and Annexon, among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Sean Bohen
President and Chief Executive Officer
◇—◇◇◇—◇◇
Shane Kovacs
Chief Operating and Financial Officer
◇—◇◇◇—◇◇
Naseem Zojwalla
Chief Medical Officer
◇◇◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Sean Bohen
President and Chief Executive Officer
◇——◇◇—◇◇
Shane Kovacs
Chief Operating and Financial Officer
◇——◇◇—◇◇
Cyrus Harmon
Former Chief Research Officer and Former Chief Executive Officer
Departed during or after this year
◇——◇◇—◇◇
Naseem Zojwalla
Chief Medical Officer
◇——◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Sean Bohen
President and Chief Executive Officer
◇——◇◇—◇◇
Shane Kovacs
Chief Operating and Financial Officer
◇——◇◇—◇◇
Naseem Zojwalla
Chief Medical Officer
◇——◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Sean Bohen
President and Chief Executive Officer
◇——◇◇—◇◇
Shawnte Mitchell
Chief Legal Officer and Corporate Secretary
◇◇—◇◇—◇◇
Shane Kovacs
Chief Operating and Financial Officer
◇——◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Sean BohenOption——————◇
Shane KovacsOption——————◇
Shawnte MitchellOption——————◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Sean BohenOption◇—◇2/28/2035
Option◇—◇2/1/2034
Option◇—◇1/31/2033
Option◇—◇1/31/2032
Shawnte MitchellOption◇—◇2/28/2035
Shane KovacsOption◇—◇2/28/2035
Option◇—◇2/1/2034
Option◇—◇1/31/2033
Option◇—◇1/31/2032
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Sean Bohen
President and Chief Executive Officer · Terms as described in the company’s compensation discussion
Severance multiple◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Shane Kovacs
Chief Operating and Financial Officer · Terms as described in the company’s compensation discussion
Severance multiple◇
Severance base◇
Severance cash amount◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Shawnte Mitchell
Chief Legal Officer and Corporate Secretary · Terms as described in the company’s compensation discussion
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Ian Clark
◇—◇———◇
Cynthia Butitta
◇—◇———◇
Yi Larson
◇—◇———◇
Andrew Rappaport
◇—◇———◇
Scott Garland
◇—◇———◇
Sandra Horning, M.D
◇—◇———◇
Gorjan Hrustanovic, Ph.D
◇—◇———◇
Graham Walmsley, M.D., Ph.D
◇—◇———◇
Cyrus L. Harmon, Ph.D
◇—◇———◇
Raman (Dr.) and Sean Bohen, M.D., Ph.D served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Alector ALEC
  • Alumis ALMS
  • Amylyx Pharmaceuticals (amlx) AMLX
  • AnaptysBio ANAB
  • Annexon ANNX
  • Arcturus Therapeutics ARCT
  • Arcus Biosciences RCUS
  • Arvinas ARVN
  • Aura Biosciences AURA
  • Cogent Biosciences COGT
  • Cullinan Therapeutics CGEM
  • Erasca ERAS
  • Inhibrx Biosciences INBX
  • KalVista Pharmaceuticals KALV
  • Keros Therapeutics KROS
  • Kodiak Sciences KOD
  • Kura Oncology KURA
  • MeiraGTx MGTX
  • Nuvation Bio NUVB
  • ORIC Pharmaceuticals ORIC
  • Praxis Precision Medicines PRAX
  • Relay Therapeutics RLAY
  • Syndax Pharmaceuticals SNDX
  • Terns Pharmaceuticals TERN
  • Verastem VSTM
  • Vir Biotechnology VIR
  • Xencor XNCR
  • Zenas BioPharma ZBIO

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 17, 2026=◇◇◇
2024June 10, 2025=◇◇◇
2023June 13, 2024=◇◇◇
2022June 15, 2023=◇◇◇
2021June 16, 2022=◇◇◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Sean Bohen (President and Chief Executive Officer), FY2025 total compensation $3,178,990 (base salary $699,920) [exec_comp, SEC accession 0001193125-26-191956, filed 2026-04-29]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Tell me when Olema Pharmaceuticals files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Olema Pharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Olema Pharmaceuticals sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Olema Pharmaceuticals' disclosed peer group is defensible, who names Olema Pharmaceuticals back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
163 figures on this page: 158 cited to the filing that reported them, 5 calculated from figures it prints.
158 cited to the filing
5 calculated from the filing

Documents cited

  1. 0001193125-26-279483
    Proposal 2—Advisory Vote on Executive Compensation Final Voting Results For Against Abstain Broker Non-Votes
  2. 0001193125-26-191956
    Director Compensation for 2025 · EXECUTIVE COMPENSATION · Outstanding Equity Awards at December 31, 2025 · Summary Compensation Table
  4. 0000950170-25-086256
    Proposal 2—Advisory Vote on Executive Compensation Final Voting Results For Against Abstain Broker Non-Votes
  5. 0000950170-25-059348
    DIRECTOR COMPENSATION · Summary Compensation Table
  6. 0000950170-24-073749
  7. 0000950170-24-049287
  8. 0001558370-23-011291
  9. 0001558370-22-010221
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Olema Pharmaceuticals executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/OLMA (accessed 2026).
Short form: data: Velarion

The paid brief for Olema Pharmaceuticals

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
9 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Olema Pharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Olema Pharmaceuticals discloses

The companies named in OLMA's own disclosed peer group.

AlectorAlumisAmylyx Pharmaceuticals (amlx)AnaptysBioAnnexonArcturus TherapeuticsArcus BiosciencesArvinasAura BiosciencesCogent BiosciencesCullinan TherapeuticsErascaInhibrx BiosciencesKalVista PharmaceuticalsKeros TherapeuticsKodiak SciencesKura OncologyMeiraGTxNuvation BioORIC PharmaceuticalsPraxis Precision MedicinesRelay TherapeuticsSyndax PharmaceuticalsTerns Pharmaceuticals

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy